NEWS FROM LTS

Company News

LTS announces the appointment of David Doles as new President and Chief Executive Officer for its US affiliate LTS Corp.

LTS Lohmann Therapie-Systeme AG, the market leader for the development and manufacturing of transdermal therapeutic systems, is very pleased to announce the appointment of Mr. David Doles as the President and Chief Executive Officer for its US affiliate, LTS Lohmann Therapy Systems, Corp. effective 1 January 2020.

2019-12-17T11:38:36+01:0016.12.2019|Categories: Company News|

European patent granted for LTS’ asenapine TTS

LTS is pleased to announce that the European Patent Office has issued their decision to grant an European Patent (EP 3338768 B1) for LTS’ application relating to an asenapine transdermal therapeutic system (TTS). The asenapine TTS is a twice-weekly transdermal patch for the treatment of schizophrenia and is one of LTS’ proprietary projects. The LTS [...]

2019-10-25T18:52:29+02:0025.10.2019|Categories: Company News|

New LTS webinar

The new LTS webinar “Oral Thin Films – Tailoring Therapy Need” presented by Dr. Marco Emgenbroich will be held on Nov. 29, 3pm CET/ 9am EST. Join our free webinar.

2018-10-30T17:34:00+01:0030.10.2018|Categories: Company News|